The MedTech industry has shown resilience by outperforming stock markets despite economic challenges. Leading companies achieved an average annual shareholder return of 16.7% between 2020 and 2023, surpassing both the broader MedTech industry and major market indices like the S&P 500 and MSCI World Index. However,
MedTech companies need to improve operational efficiency and embrace innovation to sustain growth. High-performing companies, or “winners,” managed to limit COGS increases and achieved an average revenue growth of 16% per year. They invested 7.3% of revenue in research and development, compared to 5.1% by underperformers. To maintain competitiveness, companies must optimize manufacturing processes, adopt next-generation sales models, and leverage artificial intelligence. North American MedTech companies led in revenue and margins, while European and Asian markets faced slower growth. The outlook for 2024 suggests slight improvements across regions, indicating potential stabilization ahead.
